Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.39 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HMGCR | P04035 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | PGD | P52209 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6356991 | 0.81 | CACNA2D1 (0.36) | SLC22A6TDP1CACNA2D1ADRA1ACACNB3 | |
| SCHEMBL7920450 | 0.79 | ADRA1A (0.34) | SLC22A6TDP1CACNA2D1ADRA1ACACNB3 | |
| SCHEMBL7927449 | 0.79 | ADRA1A (0.34) | SLC22A6TDP1CACNA2D1ADRA1ACACNB3 | |
| SCHEMBL15905917 | 0.77 | ALDH1A1 (0.48) | TDP1 | |
| SCHEMBL28551189 | 0.77 | SLC22A6 (0.43) | SLC22A6TDP1CACNA2D1ADRA1ACACNB3 | |
| SCHEMBL23913764 | 0.74 | SLC22A6 (0.41) | SLC22A6TDP1CACNA2D1ADRA1ACACNB3 | |
| SCHEMBL6805671 | 0.74 | PGD (0.50) | SLC22A6TDP1ADRA1ASMN1; SMN2HMGCR | |
| SCHEMBL20711453 | 0.74 | SLC22A6 (0.41) | SLC22A6TDP1CACNA2D1ADRA1ACACNB3 | |
| SCHEMBL667280 | 0.74 | PGD (0.50) | SLC22A6TDP1ADRA1ASMN1; SMN2HMGCR | |
| SCHEMBL10034531 | 0.74 | ECE1 (0.35) | TDP1TSHRCYP2C19LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9610263-B2 | Method of modulating membrane potential of a cell | VERSITECH LIMITED (CN) | 2017-04-04 | — | — | US | disclosed |
| US-8633160-B2 | Small molecule inhibitors of PDZ interactions | NONO INC. (CA) | 2014-01-21 | — | — | US | disclosed |
| US-20090163595-A1 | Method of Modulating Membrane Potential of a Cell | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2009-06-25 | — | — | US | disclosed |
| US-20090163595-A1 | Method of Modulating Membrane Potential of a Cell | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2009-06-25 | — | — | US | disclosed |
| US-20090062213-A1 | Small Molecule Inhibitors of PDZ Interactions | ARBOR VITA CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-20080227684-A1 | Small Molecule Inhibitors of PDZ Interactions | NONO INC. (CA) | 2008-09-18 | — | — | US | disclosed |
| US-5434276-A | Process for making N-acyl taurides | FINETEX, INC. (US) | 1995-07-18 | — | — | US | disclosed |
| WO-1995018095-A1 | PROCESS FOR MAKING N-ACYL TAURIDES | FINETEX, INC. (US) | 1995-07-06 | — | — | WO | disclosed |
| US-4352759-A | CRYSTALLIZATION IN ALCOHOL, AMIDATION | CHASE MANHATTAN BANK, THE NATIONAL ASSOCIATION | 1982-10-05 | — | — | US | disclosed |
| US-4233229-A | REACTING ACID CHLORIDE, TAURINE SALT, ALKALI METAL HYDROXIDE; PRECIPITATING ALKALI METAL CHLORIDE | GAF CORPORATION (US) | 1980-11-11 | — | — | US | disclosed |
| EP-0002675-A1 | Preparation of salt-free N-acyl taurines | GAF CORPORATION (US) | 1979-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062213-A1 | Small Molecule Inhibitors of PDZ Interactions | PDLIM5, DAB2IP, PSD | SLC22A6 4468/4885TDP1 2770/4885CACNA2D1 2970/4885 |
| US-20080227684-A1 | Small Molecule Inhibitors of PDZ Interactions | PDLIM5, DAB2IP, PSD | SLC22A6 4468/4885TDP1 2770/4885CACNA2D1 2970/4885 |
| US-20090163595-A1 | Method of Modulating Membrane Potential of a Cell | VDAC1, ATP2A3, ATP2A2 | SLC22A6 1030/4885TDP1 3920/4885CACNA2D1 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.